Brainstorm Cell Therapeutics Enacts Key Corporate Changes
Express News | Brainstorm Cell Therapeutics Inc Files for Mixed Shelf Offering of up to $172.6 Mln - SEC Filing
Maxim Group Maintains Brainstorm Cell Therapeutics(BCLI.US) With Buy Rating, Maintains Target Price $2
Maxim Group analyst Jason McCarthy maintains $Brainstorm Cell Therapeutics(BCLI.US)$ with a buy rating, and maintains the target price at $2.According to TipRanks data, the analyst has a success
Buy Rating Affirmed for Brainstorm Cell Therapeutics Amid Strategic Advances and Robust Financials
Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2024 Earnings Call Transcript Summary
Brainstorm Cell Therapeutics | 10-Q: Q2 2024 Earnings Report
Earnings Flash (BCLI) BRAINSTORM CELL THERAPEUTICS Reports Q2 Loss $-0.04 Per Share
Brainstorm Cell Q2 2024 GAAP EPS $(0.04), Inline. Cash And Equivalents Of $3.5M
Express News | Brainstorm Cell Therapeutics Inc - Qtrly Shr Loss $0.04
Express News | Brainstorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Express News | Brainstorm Cell Therapeutics Q2 Net Income USD -2.5 Million
Here's the Major Earnings Before the Open Tomorrow
BrainStorm Cell Therapeutics Q2 2024 Earnings Preview
Express News | Brainstorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update
BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Updates On NurOwn Stem Cell Therapy For ALS
BCLI Update - Progress Supports Our 10x Plus Value Range Potential
Express News | Brainstorm Cell Therapeutics Inc Says on July 18, Co Received Mvls Deficiency Notice From the Listing Qualifications Department Staff of Nasdaq
Maxim Group Upgrades Brainstorm Cell Therapeutics(BCLI.US) to Buy Rating, Announces Target Price $2
Maxim Group analyst Jason McCarthy upgrades $Brainstorm Cell Therapeutics(BCLI.US)$ to a buy rating, and sets the target price at $2.According to TipRanks data, the analyst has a success rate of 24.0%
Optimistic Buy Rating for Brainstorm Cell Therapeutics as NurOwn Advances Into Enhanced Phase 3b ALS Trial